Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Putting the customer first

Myer
3:27pm
March 18, 2024
Myer Holdings (ASX: MYR) operates the largest chain of premium and mid-range department stores in Australia. The business was founded 124 years ago, but even after the emergence of the suburban shopping centre and the rise of multicategory ecommerce sites, Myer has managed not just to remain relevant but is performing strongly on an active program of reinvention. Sales last year were the highest since 2005, underpinned by over 20% online penetration and more than 4m active members in its loyalty program. The balance sheet is in good shape with over $200m in net cash (excluding leases) and Myer is back to paying dividends. A new CEO, Olivia Wirth, takes the reins in June, looking to replicate with MYER one her success with the Qantas Frequent Flyer loyalty program.

Re-basing expectations

True North Copper
3:27pm
March 15, 2024
The CCP mining study details a value accretive project offering material positive cash flows from late 2024. The mining re-start will now mobilise. Execution of the CCP re-start to plan is company-defining in 2024 as TNC has an opportunity to achieve self-funding status and allay market fear of liquidity risk. We think the current share price ascribes no value to the CCP’s 4.6 year reserves, projected cash flows or mine life upside. Upside leverage to execution success is significant. Mt Oxide’s true blue-sky potential also appears overlooked. Potential returns from 8cps are substantial although we think investors do require greater risk tolerance. Demonstrating commerciality late 2024 is key.

Updating for Q1, Suncorp Bank, and 16.5% AmBank

ANZ Banking Group
3:27pm
March 14, 2024
We update our modelling for Q1 performance, inclusion of Suncorp Bank acquisition (given completion looks increasingly likely), and sale of 16.5% AmBank. Meaningful forecast upgrades because of incremental earnings from the SB acquisition now included in our modelling. We forecast earnings decline in FY24F while assumed full year inclusion of SB helps alleviate further declines in FY25F. 12 month target price lifts 9% to $26.83/sh. HOLD retained at current prices.

Implements on market buyback

Clinuvel Pharmaceuticals
3:27pm
March 14, 2024
CUV have announced an on-market buy back of approximately 3% of the shares on issue. We had been calling out for capital management and viewed this was necessary given the significant cash stockpile whilst sitting on multi-year lows. While several issues continue to present an overhang for the stock in our view, we view this as a step in the right direction. We make no changes to our valuation at this stage however given the weakness following our last note, we move back to an Add recommendation.

Heading in the right direction

Australian Vintage
3:27pm
March 12, 2024
AVG saw a material improvement in profitability during the 1H24 with underlying EBITS up 59.9% on the pcp and 41% ahead of our forecast. FY24 guidance was reiterated with AVG expecting underlying EBITDAS to be directionally aligned with FY22 reflecting easing inflation and its cost out program. We recently upgraded our recommendation for AVG to an ADD on the view that it would deliver a material earnings recovery through FY24/25. Pleasingly, AVG’s 1H24 performance demonstrates that our investment thesis remains intact and if management continues to execute there is material upside potential on offer. A decision on the China wine tariffs and any corporate activity (e.g. recently confirmed in early talks with Accolade to merge), are key near-term share price catalysts.

Waiting for reasons to upgrade

Proteomics International Laboratories
3:27pm
March 11, 2024
Following a strong run over the last month, our target price range has now been reached. At the risk of going against clear share price momentum, we continue to wait for further detail on initial launch of the PromarkerD but also note our valuation only assumes commercial success in the US. Significant upside potential remains as the rollout progresses in the US and other jurisdictions, but also view the endometriosis and oesophageal cancer diagnostics will remain key and likely hold significant value with licensing opportunities. We maintain our target price of A$1.38, but our recommendation reduces to a Hold recommendation (from Speculative Buy).

Cost out the focus in a tougher revenue environment

Livehire
3:27pm
March 4, 2024
Given the heavy cost-out initiatives implemented in recent periods (operating costs -28% on pcp), LVH’s 1H24 result showed an improved NPAT loss vs the pcp (-A$4.6m vs -A$7.2m) despite a lower overall revenue performance (1H24 operating revenue of A$3.5m, -11% on pcp). We make several changes to our assumptions over the forecast period (details below). Our price target is reduced to A$0.11 (from A$0.15).

Funding raising provides a path forward

Control Bionics
3:27pm
March 4, 2024
CBL posted its 1H24 result which was an improvement on pcp. Management believe there are sufficient funds to drive the existing business in the core regions of US and Australia as well as move forward some new product development.

Focus on 2H asset sales completing

Cromwell Property Group
3:27pm
March 3, 2024
The key focus remains on reducing gearing and completing the sale of the Polish assets. Management noted that a letter of intent has been signed with binding commitments and if successful expects the sale to occur in 4Q24. Gearing sits at 44.7% and is estimated to fall to c34% post asset sales. No FY24 guidance has been provided, however CMW expects to pay a 0.75c distribution for the March quarter. The payout ratio has fallen vs historical levels (currently around 63%) so we will be looking for further clarity on the group’s longer term payout policy post asset sales and subsequent gearing reduction. We retain a Hold rating with a revised price target of $0.46. The key near term catalyst relates to the sale of the Polish assets.

Adding further scale to Industrial Services

Acrow
3:27pm
March 1, 2024
ACF has added to its Industrial Services capability by acquiring Benchmark Scaffolding in North QLD for $9m (pre earn-outs). The acquisition represents an EV/EBITDA multiple of 3.8x (pre earn-outs), which is largely in line with the MI Scaffold acquisition in November (4x). In our view, the deal is complementary to MI Scaffold and will increase ACF’s scale in Industrial Services in QLD as well as nationally. Management has increased FY24 EBITDA guidance by $1m to between $73-76m as a result of the acquisition. This implies no change to guidance for the existing ACF business. We estimate the deal to be 2% EPS accretive in FY25 (first full year of ownership). Our target price rises to $1.43 (from $1.40) following updates to earnings forecasts and we maintain our Add rating. Trading on 9.3x FY25F PE and 4.7% yield with strong business momentum and leverage to growing civil infrastructure activity over the long term, ACF remains one of our key picks in the small caps space.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more